|
Remaining Q2 2016 Events (RVX and Zenith)
|
3
|
Resverlogix Corp.
|
May 05, 2016 11:32AM
|
|
Remaining Q2 2016 Events (RVX and Zenith)
|
1
|
Zenith Epigenetics
|
May 05, 2016 11:32AM
|
|
At least RVX has a shorter trial timeline than ESPR
|
1
|
Resverlogix Corp.
|
May 05, 2016 12:10PM
|
|
Re: At least RVX has a shorter trial timeline than ESPR
|
2
|
Resverlogix Corp.
|
May 05, 2016 12:54PM
|
|
Re: At least RVX has a shorter trial timeline than ESPR
|
4
|
Resverlogix Corp.
|
May 05, 2016 05:42PM
|
|
Updated Remaining Q2 2016 Events (RVX and Zenith)
|
2
|
Resverlogix Corp.
|
May 05, 2016 05:46PM
|
|
June 30-July 02, 2016: 9th World Drug Delivery Summit
|
|
BIOASIS TECHNOLOGIES INC
|
May 06, 2016 12:10PM
|
|
Re: Mace
|
3
|
Resverlogix Corp.
|
May 07, 2016 08:57PM
|
|
Re: Consequences of BETonMACE Findings
|
7
|
Resverlogix Corp.
|
May 10, 2016 03:03PM
|
|
Re: Consequences of BETonMACE Findings
|
3
|
Resverlogix Corp.
|
May 10, 2016 04:26PM
|
|
Re: Consequences of BETonMACE Findings
|
6
|
Resverlogix Corp.
|
May 11, 2016 10:05AM
|
|
BETonMACE now at 6-month mark
|
7
|
Resverlogix Corp.
|
May 11, 2016 10:23AM
|
|
Re: BETonMACE now at 6-month mark
|
3
|
Resverlogix Corp.
|
May 11, 2016 02:23PM
|
|
New research report 5/11/16 by Marcel Wijma, Van Leeuwenhoeck Institute
|
7
|
Resverlogix Corp.
|
May 11, 2016 02:30PM
|
|
Re: New research report 5/11/16 by Marcel Wijma, Van Leeuwenhoeck Institute
|
4
|
Resverlogix Corp.
|
May 11, 2016 04:25PM
|
|
Re: New research report 5/11/16 by Marcel Wijma, Van Leeuwenhoeck Institute
|
3
|
Resverlogix Corp.
|
May 11, 2016 09:02PM
|
|
Re: New research report 5/11/16 by Marcel Wijma, Van Leeuwenhoeck Institute
|
3
|
Resverlogix Corp.
|
May 12, 2016 10:00AM
|
|
Re: New research report 5/11/16 by Marcel Wijma, Van Leeuwenhoeck Institute
|
6
|
Resverlogix Corp.
|
May 12, 2016 11:17AM
|
|
Re: New research report 5/11/16 by Marcel Wijma, Van Leeuwenhoeck Institute
|
5
|
Resverlogix Corp.
|
May 12, 2016 12:02PM
|
|
Re: Zenith Financing Update
|
5
|
Zenith Epigenetics
|
May 13, 2016 11:47AM
|
